Supernus Up on Non-Dilutive Royalty Deal - Analyst Blog


Shutterstock photo

Supernus Pharmaceuticals, Inc. 's ( SUPN ) shares gained 3.1% following the company's announcement regarding the execution of a non-dilutive royalty deal with HealthCare Royalty Partners. Shares increased an additional 0.7% in the subsequent trading session. According to the agreement, Supernus will receive a cash payment of $30 million from the company.

As per the deal, HealthCare Royalty will acquire certain royalty and milestone rights related to the commercialization of United Therapeutics ' ( UTHR ) Orenitram (oral treprostinil), which is approved for the improvement of exercise capacity in pulmonary arterial hypertension (PAH) patients. Once a certain threshold is achieved, Supernus will retain full ownership of the royalty rights on the sales of Orenitram.

United Therapeutics and Supernus have a partnership agreement under which EnSoTrol, Supernus' osmotic delivery system has been used in the development of Orenitram.

The agreement between Supernus and HealthCare Royalty will strengthen Supernus' cash position while enhancing its operational and financial flexibility. It will position Supernus in such a manner that it can benefit from the upside potential of Orenitram going forward and partially monetize its royalty stream from the product.

We remind investors that Orenitram was launched in the U.S. market in Apr 2014. We note that subcutaneous and intravenous formulations of Orenitram are also available under the trade name Remodulin for the treatment of PAH. An application for orphan drug designation for Orenitram is under FDA review.

Supernus holds a Zacks Rank #2 (Buy). Some better-ranked stocks in the healthcare sector include Mallinckrodt plc ( MNK ) and Akorn, Inc. ( AKRX ). Both carry a Zacks Rank #1 (Strong Buy). United Therapeutics carries a Zacks Rank #2.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SUPERNUS PHARMA (SUPN): Free Stock Analysis Report

UTD THERAPEUTIC (UTHR): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

AKORN INC (AKRX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: PAH , SUPN , UTHR , MNK , AKRX

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by